MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
long-term debt
$19,636M
(8985.07%↑ Y/Y)
Net earnings
$1,077M
(-18.72%↓ Y/Y)
Amortization of intangible
assets
$422M
(0.48%↑ Y/Y)
Depreciation
$381M
(13.39%↑ Y/Y)
Share-based compensation
$317M
(9.69%↑ Y/Y)
Other, net
-$295M
(-15.23%↓ Y/Y)
Net cash from (used
in) financing...
$17,313M
(942.48%↑ Y/Y)
Net cash from
operating activities
$1,315M
(-7.20%↓ Y/Y)
Canceled cashflow
$2,172M
Canceled cashflow
$1,177M
Net increase
(decrease) in cash and cash...
-$1,719M
(-58.58%↓ Y/Y)
Canceled cashflow
$18,628M
Other
-$34M
(-466.67%↓ Y/Y)
Dividends paid
$1,098M
(7.02%↑ Y/Y)
Repayments of long-term
debt
$894M
(-8.87%↓ Y/Y)
Purchases of common shares
$180M
(-35.71%↓ Y/Y)
something is missing
-$715M
Inventories
$420M
(64.71%↑ Y/Y)
Trade receivables
$42M
(-83.97%↓ Y/Y)
Net cash from (used
in) investing...
-$20,324M
(-4224.26%↓ Y/Y)
Canceled cashflow
$34M
Effect of exchange rate
changes on cash and cash...
-$23M
(-195.83%↓ Y/Y)
Acquisitions of businesses
and technologies,...
$19,798M
Acquisitions of property and
equipment
$399M
(-17.56%↓ Y/Y)
Sales (purchases) of
other investment...
$302M
(217.89%↑ Y/Y)
Back
Back
Cash Flow
Abbott_Laboratories_logo-svg
ABBOTT LABORATORIES (ABT)
Abbott_Laboratories_logo-svg
ABBOTT LABORATORIES (ABT)
source: myfinsight.com